Results 261 to 270 of about 218,137 (296)

Prognostic significance of programmed death-1 and programmed death ligand-1 proteins in breast cancer

Human Antibodies, 2022
In numerous studies related to tumor prognosis, programmed death-ligand 1 (PD-L1) has been identified as a biomarker. This work aimed to determine the prognostic importance of PD-L1 in breast cancer. We searched electronic databases such as PubMed, Google scholar, home pages of publishing groups, medical, clinical, and pharmaceutical sciences journals,
Imtiaz Mahmood, Tahir, Abdur, Rauf, Huma, Mehboob, Samia, Sadaf, Muhammad Shaiful, Alam, Fadia, Kalsoom, Abdelhakim, Bouyahya, Aicha, El Allam, Nasreddine, El Omari, Saad, Bakrim, Muhammad, Akram, Syed Kashif, Raza, Talha Bin, Emran, Yahia N, Mabkhot, Gokhan, Zengin, Marina, Derkho, Suray, Natalya, Mohammad Ali, Shariati   +17 more
openaire   +2 more sources

Resistance mechanisms to programmed cell death protein 1 and programmed death ligand 1 inhibitors

Expert Opinion on Biological Therapy, 2021
Introduction: In the past few years, administrating monoclonal humanized antibodies, namely checkpoint inhibitors, against programmed cell death protein 1 (PD-1), and its ligand (PD-L1), has yielded reassuring tumor regression rates. Anti-PD-1/PD-L1 checkpoint inhibitors disrupt the engagement of PD-1 on T-cells and their ligands on tumor or other ...
Parmida Sadat Pezeshki, Pouya Mahdavi Sharif, Nima Rezaei   +2 more
openaire   +2 more sources

Programmed death ligand 1 signals in cancer cells

Nature Reviews Cancer, 2022
The paradigm of surface-expressed programmed death ligand 1 (PDL1) signalling to immune cell programmed death 1 (PD1) to inhibit antitumour immunity has helped to develop effective and revolutionary immunotherapies using antibodies blocking these cell-extrinsic interactions.
Anand V. R. Kornepati, Ratna K. Vadlamudi, Tyler J. Curiel   +2 more
openaire   +2 more sources

Outcomes of long-term responders to anti-programmed death 1 and anti-programmed death ligand 1 when being rechallenged with the same anti-programmed death 1 and anti-programmed death ligand 1 at progression

European Journal of Cancer, 2018
Long-term responders have been observed with anti-programmed death 1 and anti-programmed death ligand 1 (anti-PD(L)1). Optimal duration of therapy in responding and stable disease (SD) patients is unclear with various attitudes encompassing treatment until progression disease, stopping therapy after a defined timeframe.We report the experience of 13 ...
A Bernard-Tessier, Antoine Hollebecque, Rastilav Bahleda   +2 more
exaly   +3 more sources

The role of programed death-ligand 1 in renal diseases

Journal of Receptors and Signal Transduction, 2020
Programed death-ligand 1 (PD-L1, B7-H1, CD274) is a coinhibitory molecule that plays a vital role in the pathogenesis of both neoplastic and nonneoplastic diseases. However, the role of PD-L1 in primary and secondary renal diseases remains to be clarified.
Yi, Wei, Zongpei, Jiang
openaire   +2 more sources

Transarterial chemoembolisation enhances programmed death‐1 and programmed death‐ligand 1 expression in hepatocellular carcinoma

Histopathology, 2021
AimsImmunotherapies represent a new alternative therapeutic approach for hepatocellular carcinomas (HCCs), and have shown promising results when used in combination therapy. The aim of this study was to evaluate the potential of transarterial chemoembolisation (TACE) to modulate programmed death‐1 (PD‐1) and programmed death‐ligand 1 (PD‐L1) expression
Ahmed Montasser, Aurélie Beaufrère, François Cauchy, Mohamed Bouattour, Olivier Soubrane, Miguel Albuquerque, Valérie Paradis   +6 more
openaire   +2 more sources

Expression of programmed cell death ligand 1 and programmed cell death 1 in cutaneous warts

Journal of the American Academy of Dermatology, 2019
Cutaneous warts have high prevalence and cause significant morbidity. Understanding the mechanisms by which warts evade the immune system could lead to targeted and improved treatments.To determine whether cutaneous warts express programmed cell death ligand 1 (PD-L1) and to characterize the expression of programmed cell death 1 (PD-1) within the ...
Wesley Y, Yu, Timothy G, Berger, Jeffrey P, North, Zoltan, Laszik, Jarish N, Cohen   +4 more
openaire   +2 more sources

Programmed death 1 and programmed death ligand 1 expressions in patients with chronic hepatitis B

Hepatobiliary & Pancreatic Diseases International, 2013
The role of programmed death 1 (PD-1) and programmed death ligand 1 (PD-L1) in persistent HBV infection is controversial. Increasing PD-1 and PD-L1 expression has been found in hepatitis B patients during immune clearance phase, but not in HBV-tolerant patients.
Wen-Jin, Zhang, Chuan-Hui, Peng, Shu-Sen, Zheng   +2 more
openaire   +2 more sources

Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy

Expert Opinion on Biological Therapy, 2013
Multiple agents targeting the immune "checkpoint" programmed death-1 (PD-1) pathway have demonstrated early evidence of durable clinical activity and an encouraging safety profile in patients with various tumor types, including some cancers, such as non-small-cell lung cancer, historically perceived as non-immunogenic and thus nonresponsive to ...
Omid, Hamid, Richard D, Carvajal
openaire   +2 more sources

Interaction of Programmed Death-1 and Programmed Death-1 Ligand-1 Contributes to Testicular Immune Privilege

Transplantation, 2009
Immune responses are tempered in immunologically privileged sites including the testis. Previous studies have shown that islet transplantation in the testis significantly prolongs islet allograft survival. However, mechanisms underlying testicular immune privilege and intratesticular allograft survival remain unclear.Allogeneic murine islets were ...
Xuyang, Cheng, Hehua, Dai, Ni, Wan, Yolonda, Moore, Ramakrishna, Vankayalapati, Zhenhua, Dai   +5 more
openaire   +2 more sources